Rick Hogrefe and Terry Beck, has been a pioneer in nucleic acid synthesis & manufacturing since its inception in 1996. TriLink operates a quality system in compliance with ICH Q7, Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients, Section 19, APIs for Use in Clinical Trials, and ISO 9001:2015 standards. With its recent facility expansion to increase cGMP capacity, TriLink provides support from initial research phases to the production of material for use in clinical trials. TriLink’s CDMO services offer a range of manufacturing grade products from discovery-grade (RUO) to its customizable intermediate-grade - GMPLink™ to full GMP-grade with scale-up and technology transfer expertise. TriLink’s proprietary CleanCap® mRNA co-transcriptional capping technology simplifies mRNA manufacturing by removing additional enzymatic steps, resulting in high capping efficiency and improved yields over traditional co-transcriptional capping methods. TriLink has scale-up expertise and unique mRNA, oligonucleotide & plasmid production capabilities for companies focused on therapeutic, vaccine, diagnostic and biopharmaceutical breakthroughs.īiopharma companies turn to TriLink as a critical supplier of modified nucleic acids and as a CDMO partner to help them move from early research into clinical trials.

TriLink BioTechnologies, part of Maravai LifeSciences, is a leading contract development and manufacturing organization (CDMO) for the synthesis of nucleic acids, NTPs and mRNA capping analogs.

Iso 9001 2015 wikipedia